RADL3 Share Price Performance
R$23.36
3.61 (18.25%)
16.2% undervalued intrinsic discount
R$27.89
Fair Value
Price R$23.36
AnalystConsensusTarget R$27.89
AnalystHighTarget R$32.00
AnalystLowTarget R$22.16
Fair ValueR$27.89
Share Pricen/a
Raia Drogasil S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
RADL3 Community Narratives
AN
Fair Value R$27.89 16.2% undervalued intrinsic discount
RADL3: Aging Population And Digital Transformation Will Lift Retail Performance
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value R$32 27.0% undervalued intrinsic discount
Digital Momentum And Demographic Shifts Will Drive Retail Health Expansion
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value R$22.16 5.4% overvalued intrinsic discount
Accelerating E-Commerce Shift And Rapid Expansion Will Compress Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Accelerating E-Commerce Shift And Rapid Expansion Will Compress Margins
Key Takeaways Rising digital adoption and intense new competition may erode margins, limit sales growth, and threaten Raia Drogasil's traditional competitive advantages. Accelerated store expansion risks market saturation, lower revenue per location, and growing costs, undermining long-term profitability.Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
R$22.16
5.4% overvalued intrinsic discount
Fair Value
Revenue
12.06% p.a.
Profit Margin
4.24%
Future PE
24.4x
Price in 2029
R$36.82
RADL3: Aging Population And Digital Transformation Will Lift Retail Performance
Key Takeaways Structural shifts in healthcare demand, digital investments, and targeted store expansion are driving market leadership, resilient sales growth, and operational efficiency gains. Enhanced automation, data-driven processes, and category mix improvements are supporting higher margins, stronger cash flow, and increased customer retention.Read more
71
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
R$27.89
16.2% undervalued intrinsic discount
Fair Value
Revenue
12.75% p.a.
Profit Margin
4.19%
Future PE
30.51x
Price in 2029
R$46.42
Digital Momentum And Demographic Shifts Will Drive Retail Health Expansion
Key Takeaways Accelerated digital transformation, AI integration, and a scaling marketplace platform are set to rapidly boost high-margin online sales, operational efficiency, and non-core revenue streams. Expansion into underpenetrated regions, rising customer loyalty, and demographic trends position the company for sustained market share gains and long-term earnings outperformance.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
R$32
27.0% undervalued intrinsic discount
Fair Value
Revenue
16.23% p.a.
Profit Margin
4.44%
Future PE
31.59x
Price in 2029
R$53.28
Trending Discussion
Recently Updated Narratives
AN
RADL3: Fair Value View Suggests Higher Margins Will Limit Future Upside
Fair Value: R$22.16 5.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RADL3: Future Returns Will Hinge On Margins And Capital Choices
Fair Value: R$27.89 16.2% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RADL3: Higher Margin Outlook Will Support Bullish Long Term Repricing
Fair Value: R$32 27.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Raia Drogasil S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 05, 2026
- 0.74
- 29.30%
- 2.93%
- 52.7%
About RADL3
- Founded
- 1905
- Employees
- 73895
- CEO
- WebsiteView website
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.
